These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23980671)

  • 1. Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer.
    Bose CK
    Future Oncol; 2013 Sep; 9(9):1257-61. PubMed ID: 23980671
    [No Abstract]   [Full Text] [Related]  

  • 2. Nerve growth factor, follicle stimulating hormone receptor and epithelial ovarian cancer.
    Bose CK
    Med Hypotheses; 2004; 63(5):917-8. PubMed ID: 15488670
    [No Abstract]   [Full Text] [Related]  

  • 3. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival.
    Lenhard M; Lennerová T; Ditsch N; Kahlert S; Friese K; Mayr D; Jeschke U
    Histopathology; 2011 May; 58(6):990-4. PubMed ID: 21585434
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
    Zhang L; Yang N; Conejo-Garcia JR; Katsaros D; Mohamed-Hadley A; Fracchioli S; Schlienger K; Toll A; Levine B; Rubin SC; Coukos G
    Clin Cancer Res; 2003 Jan; 9(1):264-72. PubMed ID: 12538479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrinology of menopause.
    Dasgupta A; Rehman HU
    Minerva Ginecol; 2006 Feb; 58(1):25-33. PubMed ID: 16498368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers.
    Williams TI; Toups KL; Saggese DA; Kalli KR; Cliby WA; Muddiman DC
    J Proteome Res; 2007 Aug; 6(8):2936-62. PubMed ID: 17583933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathologic anatomy of endocrine glands in post-menopause].
    Hustin J
    Brux Med; 1971 Feb; 51(2):73-81. PubMed ID: 5546356
    [No Abstract]   [Full Text] [Related]  

  • 9. The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.
    Lassus H; Butzow R
    Br J Cancer; 2007 May; 96(10):1621-2; author reply 1623-4. PubMed ID: 17437016
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours.
    Basille C; Olivennes F; Le Calvez J; Beron-Gaillard N; Meduri G; Lhommé C; Duvillard P; Benard J; Morice P
    Hum Reprod; 2006 Dec; 21(12):3241-5. PubMed ID: 16893916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer: age at menopause and at first oral contraceptive use.
    Franceschi S; La Vecchia C; Negri E; Booth M; Trichopoulos D
    Int J Cancer; 1992 May; 51(2):335-6. PubMed ID: 1472182
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the risk of ovarian cancer related to age at menarche and age at menopause?
    Kvåle G; Heuch I; Nilssen S
    Int J Cancer; 1992 May; 51(2):333-4. PubMed ID: 1568801
    [No Abstract]   [Full Text] [Related]  

  • 13. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review.
    Husseinzadeh N
    Gynecol Oncol; 2011 Jan; 120(1):152-7. PubMed ID: 20934205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
    Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
    Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy.
    Slotman BJ; Rao BR
    Anticancer Res; 1988; 8(3):417-34. PubMed ID: 3291746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of growth factors and steroid hormones in ovarian cancer.
    Langdon SP; Faratian D; Harrison DJ
    Onkologie; 2009 Nov; 32(11):623-4. PubMed ID: 19887864
    [No Abstract]   [Full Text] [Related]  

  • 17. The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer.
    Bălu S; Pirtea L; Gaje P; Cîmpean AM; Raica M
    Rom J Morphol Embryol; 2012; 53(3):479-83. PubMed ID: 22990536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
    Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
    Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer: biomarker proteomic diagnosis in progress.
    Zhang Y; Guo B; Bi R
    Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on reproductive senescence and biological aging: studies in genetically altered follitropin receptor knockout [FORKO] mice.
    Danilovich N; Maysinger D; Sairam MR
    Exp Gerontol; 2004; 39(11-12):1669-78. PubMed ID: 15582283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.